Posted by Michael Wonder on 22 Oct 2024
CHMP recommends the approval of Dong-A ST’s Imuldosa, a biosimilar to Stelara
21 October 2024 - Dong-A ST announced on 18 October 2024 that its biosimilar Imuldosa (ustekinumab, development code DMB-3115), referencing Stelara, has received a positive opinion from the CHMP under the EMA.
Accord Healthcare, a subsidiary of Intas Pharmaceuticals and Dong-A ST’s partner, submitted the marketing authorisation application to the EMA in June 2023.
